Ergothioneine: what did the human mushroom and capsule trials change?
In this investigation
A promising compound still needs an outcome
The earlier mushroom investigation separates verified vitamin D2, ordinary edible mushrooms and lion’s-mane extracts. Ergothioneine deserves a closer look because human intervention evidence now goes beyond observational associations. That makes the question more interesting; it does not turn another food into a requirement.
Ergothioneine comes from the diet and can accumulate in blood after oral intake. In an early placebo-controlled study in 45 healthy men aged 21–35, researchers tested 5 or 25 mg daily for one week. Uptake and retention were clear, while most measured oxidative-damage and inflammation changes were not significant. This demonstrates delivery into the body much more directly than it demonstrates a health benefit. A compound being retained, or having its own transporter, does not establish how much extra a healthy person needs. Cheah et al., 2017
The larger memory trial had a null primary result
A 2025 randomized trial in 147 adults aged 55–79 with subjective memory complaints tested 10 or 25 mg daily for 16 weeks. Participants were cognitively high functioning at baseline. Plasma ergothioneine rose substantially, but the primary composite-memory outcome did not improve versus placebo at the endpoint. The early improvement in the 25 mg group was a within-group finding and was not sustained. Selected subjective memory and sleep-initiation outcomes were favorable; those remain secondary signals rather than evidence of general cognitive enhancement. Zajac et al., 2025
The paper also reports a within-group telomere-length change. A change within the treated group does not, by itself, establish an effect relative to placebo, and a blood biomarker does not establish longer life. The trial was funded by Blue California, which supplies the studied ingredient; one author works for the company. These details do not invalidate the results, but make independent replication particularly useful. The study also reports an amendment narrowing its primary analysis to composite memory. Original trial and disclosed protocol changes
An earlier 19-person trial in adults aged at least 60 with mild cognitive impairment tested 25 mg three times weekly for a year and reported learning and neurofilament-light-chain findings. This is a small, different population, not an independent confirmation of cognitive benefit in healthy young adults. Its earlier preprint and final publication describe the same trial and should be counted once. Yau et al., 2024
Sleep findings need their endpoint context
A 2025 Japanese study used a pharmacokinetic model to select an 8 mg daily exposure for 16 weeks, then randomized 100 adults aged 40–64. Sleep-questionnaire data were available for 92. Two subjective dimensions—feeling refreshed and perceived sleep length—improved relative to placebo. Other sleep dimensions did not significantly improve, and no significant between-group brain-structure change was found. Okumura et al., 2025
A crucial qualification appears in the paper’s limitations: the registered primary endpoint was the brain-structure measure, while the sleep analyses were exploratory. The exposure model was built around a target concentration from earlier research; it does not establish a nutritional requirement or an optimal dose for everyone. The work was supported by Suntory and several authors were employees. This is worth following as a research lead, but it does not demonstrate that an ordinary mushroom portion treats insomnia or improves my training recovery. Original methods, results and limitations
The 2026 oyster-mushroom trial is closer to food
OYSCOG assigned 80 adults aged 60–80 to freeze-dried oyster-mushroom powder or an energy-matched maltodextrin placebo for 12 weeks; 72 were analyzed. Four weekly portions each corresponded to 80 g fresh mushrooms and contained 6.02 mg measured ergothioneine. Selected short-delay recall, delayed recognition and mood comparisons favored mushrooms, while several other cognitive and metabolic measures were null. Two mushroom participants withdrew with gastrointestinal symptoms. Cha et al., 2026
The favorable inflammatory findings were from rat microglial cells treated with participants’ serum in vitro. They were not a demonstrated reduction in inflammation inside the participants’ brains. The Mushroom Council funded the studentship. Post hoc comparisons were adjusted, but a broad set of outcomes and baseline differences still warrant replication. A whole-mushroom intervention also cannot isolate ergothioneine from its other constituents. Original trial
Registration was retrospective: the registry records completion in July 2024 and first submission in February 2025. A later registration cannot provide the same protection against selective outcome choices as a prospectively registered plan. NCT06846827
What remains unresolved
A 2025 protocol describes a planned, much larger mushroom-extract trial in adults aged 45–74, with two years of follow-up and cognitive outcomes. It is a plan, not an efficacy result; the separate observational follow-up described in that publication is also a different design. Neither proposed epigenetic-clock measurements nor a study’s longevity framing establish extended healthspan. Shan et al., 2025 protocol
The important gap for my situation is a reproducible functional benefit in healthy young adults using an ordinary, practical food exposure. Trials in older people with memory complaints, biomarker changes and isolated positive tasks do not fill that gap. The reviewed human studies do not establish a daily ergothioneine target, a deficiency diagnosis from a food log, or a reason to chase a particular plasma number.
A useful decision for my daily shop
Mushrooms remain an optional meal experiment. If I can buy a small portion, prepare it safely and enjoy it with chicken and rice, that is already a worthwhile reason to try it. The new evidence supports curiosity about oyster mushrooms; it does not require supplements or measured powder sachets, and it does not assign 6.02 mg to a supermarket portion whose composition has not been tested.
I would record the species, preparation, amount eaten, taste and practical burden. A favorable meal experience can justify repeating the food while the cognitive and sleep claims remain open. Vitamin D2 from verified UV treatment remains a separate vitamin D question.